Financial Performance - Pulse Biosciences reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.32, representing an earnings surprise of +18.75% [1] - The company posted revenues of $0.26 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 5.60%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on $0.5 million in revenues, and for the current fiscal year, it is -$1.66 on $3.75 million in revenues [7] Stock Performance - Pulse Biosciences shares have increased by approximately 85.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Pulse Biosciences belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Pulse Biosciences (NasdaqCM:PLSE) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAnthony Petrone - Managing Director Equity ResearchJon Skinner - CFOPaul LaViolette - Co-Chair and CEORobert Duggan - Co-ChairTrip Taylor - Principal of Investor RelationsNone - ShareholderConference Call ParticipantsJosh Jennings - Managing Director and Senior AnalystSuraj Kalia - Managing Director and Senior AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Colby, and I'll be ...

Pulse Biosciences (NasdaqCM:PLSE) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAnthony Petrone - Managing Director Equity ResearchJon Skinner - CFOPaul LaViolette - Co-Chair and CEORobert Duggan - Co-ChairTrip Taylor - Principal of Investor RelationsNone - ShareholderConference Call ParticipantsJosh Jennings - Managing Director and Senior AnalystSuraj Kalia - Managing Director and Senior AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Colby, and I'll be ...

Pulse Biosciences (NasdaqCM:PLSE) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker3Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator today. At this time, I would like to welcome you to the Pulse Biosciences Q4 and full year 2025 earnings call. All lines have been placed on mute to prevent any background noise, and after the speakers' remarks, there will be a question-and-answer session. If you'd like to ask a question at that time, please pres ...

Exhibit 99.1 Endocardial Catheter AF Ablation Surgical AF Ablation Soft Tissue Ablation "2025 was a highly productive year for Pulse Biosciences as we achieved notable milestones in each of our market development programs. Most importantly, we have advanced our nsPFA platform into late-stage clinical development to treat atrial fibrillation in both electrophysiology and cardiac surgery, receiving FDA IDE approvals to initiate both pivotal studies," said Paul LaViolette, CEO of Pulse Biosciences. "I am thril ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) Securities registered pursuant to Section 12(b) of the Act: | | | Registered | | --- | --- | --- | | Title of Each Class Common Stock, par value $0.001 per share | Trading Symbol(s) PLSE | Name of Each Exchange on Which The Nasdaq Stock Market LLC | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPO ...

Core Insights - Pulse Biosciences (PLSE) announced promising results from its first-in-human feasibility study of the nPulse Cardiac Catheter System, demonstrating effective treatment for atrial fibrillation in 150 patients with high procedural success rates and minimal adverse effects [1][4][7] Company Developments - The study reported a 100% procedural success rate at six months and 96% at one year, with an average procedure time of 65 minutes and a low incidence of serious adverse events at 1.3% [8][10] - Management emphasized the significance of these findings, highlighting the system's efficiency and clinical outcomes, and plans to initiate pivotal IDE studies in Europe and the U.S. to expand patient treatment [2][4] Market Performance - Following the announcement, PLSE shares increased by 51.6%, with a 39.5% rise over the past six months, contrasting with a 0.4% decline in the industry [3] Clinical and Commercial Outlook - The positive results from the feasibility study are expected to enhance the company's clinical and commercial prospects, with high success rates and short procedure times supporting its competitive position in the pulsed field ablation market [4][12] - The planned pivotal IDE study in the U.S. is seen as a crucial milestone for regulatory approval and market entry, potentially boosting investor sentiment and long-term revenue opportunities [4][9] Industry Context - The pulsed field ablation market is projected to grow from $1.6 billion in 2026 at a CAGR of 33.2% through 2033, driven by increasing arrhythmia prevalence and demand for minimally invasive procedures [12]

Core Viewpoint - Pulse Biosciences Inc. is experiencing a stock surge driven by positive clinical data from its nPulse Cardiac Catheter feasibility study, despite a slight decline in the broader market [1]. Group 1: Clinical Data and Study Results - The nPulse Cardiac Catheter demonstrated successful treatment outcomes for atrial fibrillation in 150 patients, with rapid procedure times and minimal adverse effects, positioning the technology as a leading market option [2]. - Findings were presented at the Annual AF Symposium 2026 in Boston, highlighting the potential of the nPulse technology to advance atrial fibrillation treatment, with plans to initiate a pivotal IDE study for additional patient treatment [3]. Group 2: Stock Performance and Technical Analysis - The stock is trading 49% above its 20-day simple moving average (SMA) and 39.4% above its 100-day SMA, indicating strong short-term momentum, although shares have decreased by 7.20% over the past 12 months [4]. - The Relative Strength Index (RSI) is at 75.62, indicating overbought territory, while the MACD is above its signal line, reflecting bullish momentum, suggesting mixed signals regarding stock performance [5]. - Benzinga Edge ranks Pulse Biosciences' stock with a strong momentum score of 68.22, indicating outperformance relative to the broader market, but caution is advised due to the overbought RSI condition [6]. Group 3: Current Stock Price Action - Pulse Biosciences shares were up 4.05% at $21.59 during premarket trading, with key resistance identified at $24.50 and key support at $20.00 [7].

Core Viewpoint - Pulse Biosciences, Inc. (PLSE) shares experienced a significant increase of 40.91 percent, rising by $5.60 to reach $19.29, likely due to the release of positive clinical data regarding the treatment of atrial fibrillation using its nPulse Cardiac Catheter [1]. Group 1 - The stock price opened at $14.95 and fluctuated between an intraday low of $14.72 and a high of $19.70 on the Nasdaq [2]. - Trading volume surged to approximately 0.65 million shares, significantly higher than the average daily volume of around 0.18 million shares [2]. - The first-in-human feasibility study successfully treated 150 patients with rapid procedure times and minimal adverse effects, with the data presented at the 31st Annual AF Symposium 2026 in Boston [2]. Group 2 - The stock is currently trading within its 52-week range of $12.56 to $22.75 [3].

Core Insights - Pulse Biosciences, Inc. has announced late-breaking clinical data from its nPulse Cardiac Catheter first-in-human feasibility study, showcasing the successful treatment of atrial fibrillation in 150 patients [1] - The study highlights rapid procedure times and minimal adverse effects associated with the use of the proprietary Nanosecond Pulsed Field Ablation technology [1] Company Overview - Pulse Biosciences, Inc. is focused on developing innovative medical technologies, specifically utilizing nanosecond PFA energy for cardiac treatments [1] - The company is publicly traded on Nasdaq under the ticker symbol PLSE [1] Clinical Study Details - The feasibility study involved 150 patients and demonstrated effective treatment outcomes for atrial fibrillation [1] - The results were presented at the 31st Annual event, indicating the significance of the findings in the medical community [1]